Metastatic radioiodine resistant thyroid cancer is associated with significant mortality and morbidity. The goal of Dr. Haugen’s laboratory is to use molecular, genetic, transgenic, and translational approaches to study pathways and test novel therapies in advanced thyroid cancer. We are developing synergistic combinations of targeted therapies, immunotherapy, and traditional cytotoxic agents to treat progressive metastatic thyroid cancer. Novel experimental approaches to the treatment include inhibition of NFkB pathway in combination with radiation therapy and docetaxel, exploiting novel tumor suppressor protein TXNIP to delay tumor growth, and facilitating anti-tumor immune response with anti-programmed death-1 (PD-1) therapy. We are interested in personalization of advanced thyroid cancer treatment based on the molecular characteristics of the tumor and use high-throughput methods to discover new pharmacogenomic relationships.